טוען...
Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer
PURPOSE: This phase 1 study evaluated the effect of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. METHODS: Patients were dosed according to hepatic function classified by modified National Cancer Institute Organ Dysfunction Working Group criteria a...
שמור ב:
| הוצא לאור ב: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7539325/ https://ncbi.nlm.nih.gov/pubmed/29468455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3517-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|